1. Introduction to Bcr-Abl Inhibitors
1.1 Overview
1.2 Evolution of Bcr-Abl Inhibitors

2. Bcr-Abl Inhibitor - Mechanism of Action
2.1 Overview
2.2 Role of Bcr-Abl Inhibitor in Cancer

3. Global Bcr-Abl Inhibitor Drug Market Insight
3.1 Current Market Scenario
3.2 Future Market Opportunity

4. Bcr-Abl Inhibitor Drug Market Regional Analysis
4.1 US
4.2 Europe
4.3 Japan
4.4 Rest of World

5. Bcr-Abl Inhibitor Drug Market by Product
5.1 First Generation Bcr-Abl Inhibitor
5.2 Second Generation Bcr-Abl Inhibitor
5.3 Third Generation Bcr-Abl Inhibitor

6. Imatinib - 1st Generation Bcr-Abl Inhibitor 2001
6.1 Overview
6.2 Patent & Exclusivity
6.3 Pricing & Dosage Analysis
6.3.1 Branded
6.3.2 Generic
6.4 Sales Analysis

7. Dasatinib - 2nd Generation Bcr-Abl Inhibitor 2006
7.1 Overview
7.2 Patent & Exclusivity
7.3 Pricing & Dosage Analysis
7.3.1 Branded
7.3.2 Generic
7.4 Sales Analysis

8. Nilotinib - 2nd Generation Bcr-Abl Inhibitor 2007
8.1 Overview
8.2 Patent & Exclusivity
8.3 Price & Dosage Analysis
8.4 Sales Analysis

9. Bosutinib - 2nd Generation Bcr-Abl Inhibitor 2012
9.1 Overview
9.2 Patent & Exclusivity
9.3 Pricing & Dosage Analysis
9.4 Sales Analysis

10. Ponatinib - 3rd Generation Bcr-Abl Inhibitor 2012
10.1 Overview
10.2 Patent & Exclusivity
10.3 Pricing & Dosage Analysis
10.4 Sales Analysis

11. Asciminib - 3rd Generation Bcr-Abl Inhibitor 2021
11.1 Overview
11.2 Patent & Exclusivity
11.3 Pricing & Dosage Analysis

12. Olverembatinib - 3rd Generation Bcr-Abl Inhibitor 2021

13. Bcr-Abl Inhibitors Sales Forecast 2022 Till 2028
13.1 Gleevec/Glivec Sales Forecast
13.2 Sprycel Sales Forecast
13.3 Tasigna Sales Forecast
13.4 Bosulif Sales Forecast
13.5 Iclusig Sales Forecast

14. Bcr-Abl Inhibitor Market Clinical Trial Insights
14.1 By Indication
14.2 By Organization
14.3 By Patient Segment
14.4 By Phase
14.5 By Status
14.6 By Region

15. Global Bcr-Abl Tyrosine Kinase Inhibitors Clinical Trials Insight By Company, Indication & Phase
15.1 Preclinical
15.2 Clinical
15.3 Phase-I
15.4 Phase-I/II
15.5 Phase-II
15.6 Phase-II/III
15.7 Registered

16. Marketed Bcr-Abl Inhibitors Clinical Trials Insight

17. Bcr-Abl Inhibitors Market Dynamics
17.1 Market Favorable Parameters
17.2 Market Challenges

18. Bcr-Abl Inhibitor Market Future Perspective

19. Competitive Landscape
19.1 Ascentage Pharma
19.2 AstraZeneca
19.3 Bristol Myers Squibb
19.4 Fusion Pharmaceuticals
19.5 Incyte Pharmaceutical
19.6 Merck
19.7 Novartis
19.8 Pfizer
19.9 Takeda Pharmaceuticals
19.10 Teva Pharmaceutical

List of Figures

Figure 1-1: Therapeutic Options for Management of CML
Figure 1-2: Evolution of Bcr-Abl Inhibitors Development
Figure 2-1: Imatinib - Mechanism of Action in CML
Figure 2-2: Pathways Regulated by Bcr-Abl in Cancer
Figure 3-1: Global - Leukemia Incidences & Death, 2020 & 2025
Figure 3-2: Bcr-Abl Inhibitor - Drugs Sales (US$ Million), 2021
Figure 3-3: Bcr-Abl Inhibitor - Drugs Sales (US$ Million), 2020
Figure 3-4: Bcr-Abl Inhibitor - Drugs Sales (US$ Million), 2019
Figure 3-5: Bcr-Abl Inhibitor - Drugs Sales (US$ Million), 2018
Figure 3-6: Bcr-Abl Inhibitor - Drugs Market by Region (US$ Billion), 2021
Figure 3-7: Bcr-Abl Inhibitor - Drugs Market by Region (%), 2021
Figure 3-8: Global - Bcr-Abl Inhibitors Drugs Market Size (US$ Billion), 2022 - 2028
Figure 4-1: US - Leukemia Incidences & Death, 2020 & 2025
Figure 4-2: US vs. ROW - Bcr-Abl Inhibitor Drugs Market (US$ Billion), 2021
Figure 4-3: US vs. ROW - Bcr-Abl Inhibitor Drugs Market (%), 2021
Figure 4-4: US - Bcr-Abl Inhibitors Drugs Market Size (US$ Billion), 2022 - 2028
Figure 4-5: Europe - Leukemia Incidences & Death, 2020 & 2025
Figure 4-6: Europe vs. ROW - Bcr-Abl Inhibitor Drugs Market (US$ Billion), 2021
Figure 4-7: Europe vs. ROW - Bcr-Abl Inhibitor Drugs Market (%), 2021
Figure 4-8: Europe - Bcr-Abl Inhibitors Drugs Market Size (US$ Million), 2022 - 2028
Figure 4-9: Japan - Leukemia Incidences & Death, 2020 & 2025
Figure 4-10: Japan vs. ROW - Bcr-Abl Inhibitor Drugs Market (US$ Billion), 2021
Figure 4-11: Japan vs. ROW - Bcr-Abl Inhibitor Drugs Market (%), 2021
Figure 4-12: Japan - Bcr-Abl Inhibitors Drugs Market Size (US$ Million), 2022 - 2028
Figure 4-13: China - Leukemia Incidences & Death, 2020 & 2025
Figure 4-14: India - Leukemia Incidences & Death, 2020 & 2025
Figure 4-15: ROW - Bcr-Abl Inhibitors Drugs Market Size (US$ Million), 2021 - 2028
Figure 4-16: China - Bcr-Abl Inhibitors Drugs Market Size (US$ Million), 2021 - 2028
Figure 5-1: First Generation vs. Others - Bcr-Abl Inhibitor Drugs Market (%), 2021
Figure 5-2: First Generation vs. Others - Bcr-Abl Inhibitor Drugs Market (%), 2021
Figure 5-3: Global - First Generation Bcr-Abl Inhibitor Drugs Market Size (US$ Million), 2022 -
2028
Figure 5-4: Second Generation vs. Others - Bcr-Abl Inhibitor Drugs Market (%), 2021
Figure 5-5: Second Generation vs. Others - Bcr-Abl Inhibitor Drugs Market (%), 2021
Figure 5-6: Second Generation Bcr-Abl Inhibitor Drugs Market by Drug Type (%), 2021
Figure 5-7: Second Generation Bcr-Abl Inhibitor Drugs Market by Drug Type (US$ Million),
2021
Figure 5-8: Global - Second Generation Bcr-Abl Inhibitor Drugs Market Size (US$ Million), 2022
- 2028
Figure 5-9: Third Generation vs. Others - Bcr-Abl Inhibitor Drugs Market (%), 2021
Figure 5-10: Third Generation vs. Others - Bcr-Abl Inhibitor Drugs Market (%), 2021
Figure 5-11: Global - Third Generation Bcr-Abl Inhibitor Drugs Market Size (US$ Million), 2022
- 2028
Figure 6-1: US - Imatinib FDA Orphan Drug Designation by Indication
Figure 6-2: Imatinib - Approval Year by Region

Figure 6-3: US - Gleevec FDA Approval History by Indication
Figure 6-4: US - Gleevec Patent Approval & Expiration Year
Figure 6-5: Imatinib - Ist Generic Approval by Region
Figure 6-6: US - Cost of Supply of 90 Tablets & Per Unit Cost of Gleevec 100mg (US$),
March'2022
Figure 6-7: US - Cost of Supply of 30 Tablets & Per Unit Cost of Gleevec 400mg (US$),
March'2022
Figure 6-8: UK - Cost of Supply of 60 Tablets & Per Unit Cost of Glivec 100mg (GBP/US$),
March'2022
Figure 6-9: UK - Cost of Supply of 30 Tablets & Per Unit Cost of Glivec 400mg (GBP/US$),
March'2022
Figure 6-10: US - Cost of Supply of 20 Tablets & Per Unit Cost of Imatinib 100mg (US$),
March'2022
Figure 6-11: US - Cost of Supply of 30 Tablets & Per Unit Cost of Imatinib 100mg (US$),
March'2022
Figure 6-12: US - Cost of Supply of 90 Tablets & Per Unit Cost of Imatinib 100mg (US$),
March'2022
Figure 6-13: US - Cost of Supply of 20 Tablets & Per Unit Cost of Imatinib 400mg (US$),
March'2022
Figure 6-14: US - Cost of Supply of 30 Tablets & Per Unit Cost of Imatinib 400mg (US$),
March'2022
Figure 6-15: UK - Cost of Supply of 60 Tablets & Per Unit Cost of Imatinib 100mg (GBP/US$),
March'2022
Figure 6-16: UK - Cost of Supply of 30 Tablets & Per Unit Cost of Glivec 400mg (GBP/US$),
March'2022
Figure 6-17: Imatinib - Recommended Initial Dose in Adult by Therapeutic Condition (mg/day)
Figure 6-18: Global - Gleevec/Glivec Annual Sales (US$ Million), 2018-2021
Figure 6-19: Global - Gleevec/Glivec Quarterly Sales (US$ Million), 2021
Figure 6-20: Global - Gleevec/Glivec Quarterly Sales (US$ Million), 2019 & 2020
Figure 7-1: US - Sprycel Orphan Drug Designation Approval & Exclusivity for CML
Figure 7-2: US - Sprycel Orphan Drug Designation Approval & Exclusivity for Ph+ ALL
Figure 7-3: US - Sprycel Orphan Drug Designation & FDA Approval Year
Figure 7-4: Sprycel - Approval Year by Region
Figure 7-5: US - Sprycel Approval Year by Indication
Figure 7-6: US - Sprycel Patent Approval & Expiration Year
Figure 7-7: Japan - Sprycel Approval & Patent Exclusivity Year
Figure 7-8: Europe - Branded & 1st Generic Approval Year
Figure 7-9: US - Cost of Supply of 60 Tablets & Per Unit Cost of Sprycel 20mg (US$),
March'2022
Figure 7-10: US - Cost of Supply of 60 Tablets & Per Unit Cost of Sprycel 50mg & 70mg (US$),
March'2022
Figure 7-11: US - Cost of Supply of 60 Tablets & Per Unit Cost of Sprycel 80mg, 100mg &
140mg (US$), March'2022
Figure 7-12: UK - Cost of Supply of 60 Tablets & Per Unit Cost of Sprycel 20mg (GBP/US$),
March'2022
Figure 7-13: UK - Cost of Supply of 30 Tablets & Per Unit Cost of Sprycel 50mg, 80mg, 100mg
& 140mg (GBP/US$), March'2022
Figure 7-14: UK - Cost of Supply of 60 Tablets & Per Unit Cost of Sprycel 20mg (GBP/US$),
March'2022

Figure 7-15: UK - Cost of Supply of 30 Tablets & Per Unit Cost of Sprycel 50mg, 80mg, 100mg
& 140mg (GBP/US$), March'2022
Figure 7-16: Dasatinib - Initial Recommended Dose by Indication for Adults (mg/day)
Figure 7-17: Dasatinib - Initial Recommended Dose by Indication for Pediatric Patients by
Weight (mg/day)
Figure 7-18: Global - Sprycel Annual Sales (US$ Million), 2017-2021
Figure 7-19: US - Sprycel Annual Sales (US$ Million), 2017-2021
Figure 7-20: Sprycel - Annual Sales by Region (US$ Million), 2021
Figure 7-21: Sprycel - Annual Sales by Region (%), 2021
Figure 7-22: Sprycel - Annual Sales by Region (%), 2020
Figure 7-23: Global - Sprycel Quarterly Sales (US$ Million), 2021
Figure 7-24: US - Sprycel Quarterly Sales (US$ Million), 2021
Figure 7-25: Global - Sprycel Quarterly Sales (US$ Million), 2020
Figure 7-26: US - Sprycel Quarterly Sales (US$ Million), 2020
Figure 8-1: US - Tasgina Orphan Drug Designation Approval & Exclusivity for CML
Figure 8-2: Tasigna - Approval Year by Region
Figure 8-3: US - Tasigna Orphan Drug Designation & Approval Year
Figure 8-4: Europe - Tasigna Orphan Drug Designation & Approval Year
Figure 8-5: US - Tasigna Approval History by Indication
Figure 8-6: US - Tasigna Patent Approval & Expiration Year
Figure 8-7: Canada - Tasigna Patent Approval & Expiration Year
Figure 8-8: US - Tasigna FDA Approval & Patent Exclusivity Year
Figure 8-9: Europe - Tasigna EMA Approval & Patent Exclusivity Year
Figure 8-10: US - Cost of Supply of 120 Capsules & Per Unit Cost of Tasigna 50mg (US$),
March'2022
Figure 8-11: US - Cost of Supply of 28 Capsules & Per Unit Cost of Tasigna 150mg & 200mg
(US$), March'2022
Figure 8-12: US - Cost of Supply of 112 Capsules & Per Unit Cost of Tasigna1500mg & 200mg
(US$), March'2022
Figure 8-13: UK - Cost of Supply of 120 Capsules & Per Unit Cost of Tasigna 50mg (GBP/US$),
March'2022
Figure 8-14: UK - Cost of Supply of 112 Capsules & Per Unit Cost of Tasigna 150mg & 200mg
(GBP/US$), March'2022
Figure 8-15: Nilotinib - Initial Recommended Dose by Indication (mg/day)
Figure 8-16: Nilotinib - Minimum & Maximum Recommended Dose in Pediatric CML (mg/day)
Figure 8-17: Global - Tasigna Annual Sales (US$ Million), 2018-2021
Figure 8-18: Global - Tasigna Quarterly Sales (US$ Million), 2021
Figure 8-19: Global - Tasigna Quarterly Sales (US$ Million), 2019 & 2020
Figure 9-1: US - Bosulif Orphan Drug Designation Approval & Exclusivity for CML
Figure 9-2: Bosulif - Approval Year by Region
Figure 9-3: US - Bosulif Orphan Drug Designation & Approval Year
Figure 9-4: US - Bosulif Approval by Indication
Figure 9-5: US - Bosulif Patent Approval & Expiration Year
Figure 9-6: Europe - Bosutif EMA Approval & Patent Exclusivity Year
Figure 9-7: US - Cost of Supply of 120 Tablets & Per Unit Cost of Bosulif 100mg (US$),
March'2022
Figure 9-8: US - Cost of Supply of 120 Tablets & Per Unit Cost of Bosulif 400mg & 500mg
(US$), March'2022

Figure 9-9: UK - Cost of Supply of 28 Tablets & Per Unit Cost of Basulif 100mg (GBP/US$),
March'2022
Figure 9-10: UK - Cost of Supply of 28 Tablets & Per Unit Cost of Basulif 400mg & 500mg
(GBP/US$), March'2022
Figure 9-11: Bosutinib - Initial Recommended Dose by Indication for Adults (mg/day)
Figure 9-12: Bosutinib - Minimum & Maximum Recommended Dose (mg/day)
Figure 9-13: Global - Bosulif Annual Sales (US$ Million), 2017-2021
Figure 9-14: US - Bosulif Annual Sales (US$ Million), 2017-2021
Figure 9-15: Europe - Bosulif Annual Sales (US$ Million), 2017-2021
Figure 9-16: Bosulif - Annual Sales by Region (US$ Million), 2021
Figure 9-17: Bosulif - Annual Sales by Region (%), 2021
Figure 9-18: Bosulif - Annual Sales by Region (%), 2020
Figure 9-19: Global - Bolusif Quarterly Sales (US$ Million), 2021
Figure 9-20: US - Bolusif Quarterly Sales (US$ Million), 2021
Figure 9-21: Europe - Bolusif Quarterly Sales (US$ Million), 2021
Figure 9-22: Global - Bosulif Quarterly Sales (US$ Million), 2020
Figure 9-23: US - Bosulif Quarterly Sales (US$ Million), 2020
Figure 10-1: Iclusig - Orphan Drug Designation by Region
Figure 10-2: US - Iclusig Orphan Drug Designation & Approval Year
Figure 10-3: Europe - Iclusig Orphan Drug Designation & Approval Year
Figure 10-4: Iclusig - Approval Year by Region
Figure 10-5: US - Iclusig Approval by Indication
Figure 10-6: US - Iclusig Patent Approval & Expiration Year
Figure 10-7: Europe - Iclusig EMA Approval & Patent Exclusivity Year
Figure 10-8: Japan - Iclusig Approval & Patent Exclusivity Year
Figure 10-9: US - Cost of Supply of 30 Tablets & Per Unit Cost of Iclusig Oral Tablet (US$),
March'2022
Figure 10-10: UK - Cost of Supply of 30 Tablets & Per Unit Cost of Iclusig 15mg (GBP/US$),
March'2022
Figure 10-11: UK - Cost of Supply of 30 Tablets & Per Unit Cost of Iclusig 30mg & 45mg
(GBP/US$), March'2022
Figure 10-12: Ponatinib - Initial & Dose Reductions for CP-CML (mg/day)
Figure 10-13: Ponatinib - Initial & Dose Reductions for Resistant CML & Ph+ ALL (mg/day)
Figure 10-14: Global - Inclusig Annual Sales (US$ Million), 2017-2021
Figure 10-15: Global - Inclusig Quarterly Sales (US$ Million), 2021
Figure 10-16: Global - Inclusig Quarterly Sales (US$ Million), 2019 & 2020
Figure 11-1: US - Scemblix Orphan Drug Designation & Approval Year
Figure 11-2: US - Scemblix Patent Issue & Expiration Year
Figure 11-3: US - Scemblix FDA Approval & Patent Exclusivity Year
Figure 11-4: US - Cost of Supply of 60 Tablets & Per Unit Cost of Scemblix Oral Tablet (US$),
March'2022
Figure 11-5: Scemblix - Initial & Dose Reductions for Ph+ CML-CP, Previously Treated with
Two or More TKIs (mg/day)
Figure 11-6: Scemblix - Initial & Dose Reductions for Ph+ CML-CP with the T315I Mutation
(mg/day)
Figure 12-1: China - Olverembatinib Priority Review, Breakthrough Therapy Designation &
NMPA Approval Year

Figure 12-2: Olverembatinib - Orphan Designation by Region
Figure 13-1: Global - Glivec/Gleevec Sales Forecast (US$ Million), 2022 - 2028
Figure 13-2: Global - Sprycel Sales Forecast (US$ Million), 2022 - 2028
Figure 13-3: US - Sprycel Sales Forecast (US$ Million), 2022 - 2028
Figure 13-4: ROW - Sprycel Sales Forecast (US$ Million), 2022 - 2028
Figure 13-5: Global - Tasigna Sales Forecast (US$ Million), 2022 - 2028
Figure 13-6: Global - Bolusif Sales Forecast (US$ Million), 2022 - 2028
Figure 13-7: US - Bolusif Sales Forecast (US$ Million), 2022 - 2028
Figure 13-8: Europe - Bolusif Sales Forecast (US$ Million), 2022 - 2028
Figure 13-9: ROW - Bolusif Sales Forecast (US$ Million), 2022 - 2028
Figure 13-10: Global - Iclusig Sales Forecast (US$ Million), 2022 - 2028
Figure 14-1: BCR-ABL Inhibitor - Number of Drugs in Clinical Trials by Indication, April'2022
Figure 14-2: BCR-ABL Inhibitor - Number of Drugs in Clinical Trials by organization, April'2022
Figure 14-3: BCR-ABL Inhibitor - Number of Drugs in Clinical Trials by Patient Segment,
April'2022
Figure 14-4: BCR-ABL Inhibitor - Number of Drugs in Clinical Trials by Phase, April'2022
Figure 14-5: BCR-ABL Inhibitor - Number of Clinical Trials by Status, March'2022
Figure 14-6: BCR-ABL Inhibitor - Number of Clinical Trials by Region, March'2022
Figure 14-7: North America - Bcr-Abl Inhibitors Number of Clinical Trial by Countries,
March'2022
Figure 17-1: Bcr-Abl Inhibitor Market - Favorable Parameters
Figure 17-2: BCR-ABL Inhibitor Market Challenges

Companies Mentioned
. Ascentage Pharma
. AstraZeneca
. Bristol Myers Squibb
. Fusion Pharmaceuticals
. Incyte Pharmaceutical
. Merck
. Novartis
. Pfizer
. Takeda Pharmaceuticals
. Teva Pharmaceutical
.